How were LadRx's earnings last quarter?

LadRx Co. (OTCMKTS:CYTR) posted its quarterly earnings data on Friday, August, 9th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02.

When did LadRx's stock split?

Shares of LadRx reverse split on the morning of Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 31st 2017. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of LadRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LadRx investors own include Anavex Life Sciences (AVXL) , Biopharmx (BPMX) , Rexahn Pharmaceuticals (REXN) , Idera Pharmaceuticals (IDRA) , Arrowhead Pharmaceuticals (ARWR) , Aurinia Pharmaceuticals (AUPH) , Synergy Pharmaceuticals (SGYP) , Marinus Pharmaceuticals (MRNS) and

How do I buy shares of LadRx?

Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:CYTR

LadRx (CYTR) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free CYTR Stock Alerts

Compare

Today's Range: N/A
50-Day Range: $0.09
▼
$0.09
52-Week Range: N/A

Volume: 4,000 shs
Average Volume: 99,706 shs
Market Capitalization: $4.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get LadRx alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About LadRx Stock (OTCMKTS:CYTR)

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

CYTR Stock News Headlines

August 11, 2023 | finance.yahoo.com

LadRx Corporation (LADX) Stock Historical Prices & Data - Yahoo Finance

November 27, 2022 | finance.yahoo.com

LadRx Corporation Issues Corporate Update for 3Q22

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

October 5, 2022 | businesswire.com

LadRx Corporation Announces OTCQB Ticker Change to LADX - Business Wire

September 23, 2022 | marketscreener.com

CYTRX CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

September 23, 2022 | businesswire.com

CytRx Corporation Relaunches as LadRx Corporation - Business Wire

September 7, 2022 | businesswire.com

European Patent Office Awards CytRx Key Patent - Business Wire

August 25, 2022 | marketscreener.com

ADIAL PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

August 21, 2022 | reuters.com

CYTR.PK - CytRx Corporation | Stock Price & Latest News | Reuters

August 9, 2022 | businesswire.com

CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors - Business Wire

August 9, 2022 | finance.yahoo.com

CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

July 27, 2022 | marketscreener.com

CYTRX CORP : Submission of Matters to a Vote of Security Holders (form 8-K) - Marketscreener.com

May 20, 2022 | stockhouse.com

2022-05-19 | OTCQB:CYTR | Press Release | CytRx Corporation - Stockhouse

May 20, 2022 | businesswire.com

CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Business Wire

May 20, 2022 | marketscreener.com

CYTRX CORP : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

May 19, 2022 | finance.yahoo.com

CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Yahoo Finance

May 19, 2022 | marketscreener.com

CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Marketscreener.com

May 17, 2022 | finance.yahoo.com

CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

May 16, 2022 | streetinsider.com

Arcellx (ACLX) Appoints Olivia Ware to its Board - StreetInsider.com

April 20, 2022 | businesswire.com

CytRx Partners with Oncology Development Expert to Advance LADR Platform - Business Wire

April 20, 2022 | finance.yahoo.com

CytRx Partners with Oncology Development Expert to Advance LADR Platform

April 13, 2022 | prnewswire.com

Gene Therapies & Associated Vectors 2022: Intellectual Property Landscape, Patent Valuation Analysis, Granted Patents and Claims Analysis - PR Newswire

March 25, 2022 | streetinsider.com

Form 424B3 CYTRX CORP - StreetInsider.com

March 23, 2022 | benzinga.com

CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress - Benzinga - Benzinga

March 23, 2022 | marketscreener.com

CYTRX CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com

March 21, 2022 | finance.yahoo.com

CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress - Yahoo Finance

See More Headlines

Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/09/2019
Today: 4/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Current Symbol: OTCMKTS:CYTR
CUSIP: N/A
CIK: 799698
Web: www.cytrx.com
Phone: (310) 826-5648
Fax: 310-826-6139
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,700,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -67.61%
Return on Assets: -45.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.94
Quick Ratio: 5.94

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.24 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 45,037,000
Free Float: 33,834,000
Market Cap: $4.14 million
Optionable: Not Optionable
Beta: 1.96

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. John Y. Caloz (Age 70)
CFO, Treasurer & Sr. VP
Comp: $500k
Dr. Stephen Snowdy Ph.D. (Age 52)
Chief Exec. Officer
Molly Carey Poarch
Global & U.S. Head of Corp. Communications
Ms. Molly Painter (Age 46)
Pres of USA and Head of Launch & Commercial Operations
Terri Stevens
Chief Bus. Officer
Ms. Cristina Newman
Corp. Sec.
Dr. Felix Kratz Ph.D. (Age 59)
Sr. VP, Drug Devel.

Key Competitors

View All Competitors

CYTR Stock Analysis - Frequently Asked Questions

How were LadRx's earnings last quarter?: LadRx Co. (OTCMKTS:CYTR) posted its quarterly earnings data on Friday, August, 9th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02.
When did LadRx's stock split?: Shares of LadRx reverse split on the morning of Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 31st 2017. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.
What other stocks do shareholders of LadRx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other LadRx investors own include Anavex Life Sciences (AVXL), Biopharmx (BPMX), Rexahn Pharmaceuticals (REXN), Idera Pharmaceuticals (IDRA), Arrowhead Pharmaceuticals (ARWR), Aurinia Pharmaceuticals (AUPH), Synergy Pharmaceuticals (SGYP), Marinus Pharmaceuticals (MRNS) and
How do I buy shares of LadRx?: Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CYTR) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

LadRx (CYTR) Stock Price, News & Analysis

About LadRx Stock (OTCMKTS:CYTR)

CYTR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CYTR Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info